Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARDT NYSE:AUNA NASDAQ:CDNA NASDAQ:PSNL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health$7.95-14.2%$9.40$7.71▼$15.48$1.14B0.84408,170 shs1.55 million shsAUNAAuna$4.52+0.4%$5.20$4.09▼$6.85$334.53M0.81413,466 shs128,003 shsCDNACareDx$22.13+0.2%$19.85$10.96▼$23.24$1.14B2.49707,113 shs425,234 shsPSNLPersonalis$10.81-3.0%$6.95$3.84▼$11.85$1.13B2.281.81 million shs2.26 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health+0.23%-0.58%-8.66%-3.48%-35.83%AUNAAuna-0.55%+7.50%-12.18%-10.95%-30.54%CDNACareDx-3.20%+2.46%+2.65%+15.79%+29.22%PSNLPersonalis-1.07%+24.61%+92.73%+24.75%+130.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health$7.95-14.2%$9.40$7.71▼$15.48$1.14B0.84408,170 shs1.55 million shsAUNAAuna$4.52+0.4%$5.20$4.09▼$6.85$334.53M0.81413,466 shs128,003 shsCDNACareDx$22.13+0.2%$19.85$10.96▼$23.24$1.14B2.49707,113 shs425,234 shsPSNLPersonalis$10.81-3.0%$6.95$3.84▼$11.85$1.13B2.281.81 million shs2.26 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health+0.23%-0.58%-8.66%-3.48%-35.83%AUNAAuna-0.55%+7.50%-12.18%-10.95%-30.54%CDNACareDx-3.20%+2.46%+2.65%+15.79%+29.22%PSNLPersonalis-1.07%+24.61%+92.73%+24.75%+130.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDTArdent Health 2.36Hold$14.2178.72% UpsideAUNAAuna 2.40Hold$6.9754.13% UpsideCDNACareDx 2.00Hold$25.0012.99% UpsidePSNLPersonalis 2.57Moderate Buy$11.001.80% UpsideCurrent Analyst Ratings BreakdownLatest AUNA, ARDT, PSNL, and CDNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026CDNACareDx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/26/2026AUNAAuna JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$6.00 ➝ $5.005/12/2026PSNLPersonalis Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$10.00 ➝ $9.005/11/2026PSNLPersonalis BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.005/7/2026ARDTArdent Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $13.504/29/2026CDNACareDx BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$26.00 ➝ $28.004/21/2026PSNLPersonalis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026AUNAAuna Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/27/2026AUNAAuna Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/25/2026ARDTArdent Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/9/2026ARDTArdent Health Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$14.00 ➝ $13.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDTArdent Health$6.32B0.18$2.37 per share3.35$11.78 per share0.67AUNAAuna$1.23B0.27$1.95 per share2.32$6.70 per share0.67CDNACareDx$379.80M3.01$0.01 per share3,500.48$5.89 per share3.76PSNLPersonalis$69.65M16.25N/AN/A$2.94 per share3.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDTArdent Health$135.81M$0.958.376.572.052.09%13.85%4.48%8/4/2026 (Estimated)AUNAAuna$27.39M$0.2617.394.61N/A1.53%16.25%4.03%8/18/2026 (Estimated)CDNACareDx-$21.35M-$0.16N/A73.75N/A-2.01%-2.65%-1.96%8/5/2026 (Estimated)PSNLPersonalis-$81.27M-$1.02N/AN/AN/A-148.11%-43.52%-32.92%8/4/2026 (Estimated)Latest AUNA, ARDT, PSNL, and CDNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AUNAAuna$0.19$0.0510-$0.1390$0.03$320.54 million$336.84 million5/7/2026Q1 2026PSNLPersonalis-$0.23-$0.29-$0.06-$0.29$14.49 million$15.47 million5/5/2026Q1 2026ARDTArdent Health$0.18$0.28+$0.10$0.28$1.58 billion$1.60 billion4/28/2026Q1 2026CDNACareDx$0.11$0.34+$0.23$0.05$102.03 million$117.70 million3/10/2026Q4 2025AUNAAuna$0.11$0.53+$0.42$1.33$1.08 billion$336.67 million3/4/2026Q4 2025ARDTArdent Health$0.35$0.32-$0.03$0.32$1.63 billion$1.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDTArdent HealthN/AN/AN/AN/AN/AAUNAAunaN/AN/AN/AN/AN/ACDNACareDxN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDTArdent Health0.622.122.00AUNAAuna1.761.091.00CDNACareDxN/A3.403.07PSNLPersonalisN/A6.616.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDTArdent HealthN/AAUNAAunaN/ACDNACareDxN/APSNLPersonalis61.91%Insider OwnershipCompanyInsider OwnershipARDTArdent Health1.90%AUNAAunaN/ACDNACareDx2.40%PSNLPersonalis4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDTArdent Health25,200143.35 million140.63 millionOptionableAUNAAuna15,25474.01 millionN/AN/ACDNACareDx74051.66 million50.42 millionOptionablePSNLPersonalis400104.72 million100.32 millionOptionableAUNA, ARDT, PSNL, and CDNA HeadlinesRecent News About These CompaniesPersonalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026June 2 at 8:43 AM | finance.yahoo.comAssessing Personalis (PSNL) Valuation After Its Strong Recent Share Price MomentumJune 2 at 8:43 AM | finance.yahoo.comPersonalis (NASDAQ:PSNL) CFO Sells $449,292.42 in StockJune 1 at 5:28 AM | americanbankingnews.comPersonalis (NASDAQ:PSNL) CEO Sells $219,397.18 in StockJune 1 at 4:43 AM | americanbankingnews.comChristopher Hall Sells 80,091 Shares of Personalis (NASDAQ:PSNL) StockMay 31 at 4:59 AM | americanbankingnews.comInsider Selling: Personalis (NASDAQ:PSNL) CEO Sells 19,909 Shares of StockMay 30, 2026 | insidertrades.comPersonalis (NASDAQ:PSNL) Upgraded at Wall Street ZenMay 30, 2026 | americanbankingnews.comPersonalis: Initiating Coverage Of Cancer Testing Biotech With A Buy RatingMay 28, 2026 | seekingalpha.comPersonalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx ConsortiumMay 26, 2026 | finance.yahoo.comNeedham Remains a Buy on Personalis (PSNL)May 25, 2026 | theglobeandmail.comPersonalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 25, 2026 | americanbankingnews.comUS Agency Broadens Coverage Of Personalis Breast Cancer TestMay 20, 2026 | benzinga.comPersonalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment MonitoringMay 20, 2026 | businesswire.comPersonalis to Participate in Upcoming Investor EventsMay 14, 2026 | businesswire.comPersonalis Shareholders Back Directors, Auditor and Executive PayMay 13, 2026 | tipranks.comPersonalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid TumorsMay 13, 2026 | businesswire.comBTIG Research Issues Pessimistic Forecast for Personalis (NASDAQ:PSNL) Stock PriceMay 11, 2026 | marketbeat.comGuggenheim Remains a Buy on Personalis (PSNL)May 10, 2026 | theglobeandmail.comPersonalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street ZenMay 9, 2026 | marketbeat.comPersonalis: Q1 Earnings SnapshotMay 8, 2026 | ctpost.comCPersonalis (PSNL) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUNA, ARDT, PSNL, and CDNA Company DescriptionsArdent Health NYSE:ARDT$7.95 -1.32 (-14.24%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Auna NYSE:AUNA$4.52 +0.02 (+0.44%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.CareDx NASDAQ:CDNA$22.12 +0.06 (+0.25%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Personalis NASDAQ:PSNL$10.80 -0.34 (-3.01%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
